The FDA just handed this clinical-stage biotech its golden ticket -- but at a $4.3 billion valuation, the market's already pricing in a fair amount of commercial success.

CRNX

<p>美国食品药品监督管理局刚刚给予这家临床阶段生物技术公司一张 “金票”——但以 43 亿美元的估值，市场已经在定价中考虑了相当程度的商业成功</p>

Crinetics Pharmaceuticals 的股票是否值得购买？